{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:30:14Z","timestamp":1792639814646,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T00:00:00Z","timestamp":1409097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ctrv.2014.08.001","type":"journal-article","created":{"date-parts":[[2014,8,24]],"date-time":"2014-08-24T12:38:24Z","timestamp":1408883904000},"page":"1080-1088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Therapeutic options in relapsed or refractory peripheral T-cell lymphoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Bertrand","family":"Coiffier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dearden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gomes da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Pettengell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhart","family":"Weidmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"d\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2014.08.001_b0005","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.ctrv.2014.08.001_b0010","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrclinonc.2011.51","article-title":"Hematology: relapsed and refractory PTCL\u2013into the therapeutic abyss","volume":"8","author":"Foss","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0020","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0025","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0030","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0035","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0040","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2014.08.001_b0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group","volume":"79","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0050","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0055","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0060","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2014.08.001_b0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"Friedberg","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.ctrv.2014.08.001_b0070","article-title":"Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL): results from the BELIEF trial","volume":"31","author":"O\u2019Connor","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0075","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0080","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0085","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0090","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0095","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0100","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0110","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0115","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.08.001_b0120","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2011.573031","article-title":"Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified","volume":"52","author":"Zinzani","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2014.08.001_b0125","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0130","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000227554","article-title":"Pentostatin (2\u2032-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group","volume":"53","author":"Monfardini","year":"1996","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2014.08.001_b0140","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.08.001_b0145","first-page":"1513","article-title":"Pentostatin in T-non-Hodgkin\u2019s lymphomas: efficacy and effect on CD26+ T lymphocytes","volume":"10","author":"Dang","year":"2003","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2014.08.001_b0150","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2012.069757","article-title":"Multicenter phase II study of plitidepsin in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma","volume":"98","author":"Ribrag","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2014.08.001_b0155","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II\u2013I\u2013II study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O\u2019Connor","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0160","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0165","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0170","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0180","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2011-02-334904","article-title":"Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas","volume":"118","author":"Witzig","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0185","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma","volume":"150","author":"d\u2019Amore","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0190","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.08.001_b0195","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0200","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","article-title":"A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0205","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0210","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"CAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0215","article-title":"First interim efficacy and safety analysis of an international phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with chemotherapy with or without alemtuzumab and consolidated by high dose therapy","volume":"120","author":"d\u2019Amore","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0220","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2014.08.001_b0225","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1054\/bjoc.2000.1327","article-title":"P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228","volume":"83","author":"Sandor","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.08.001_b0230","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2014.08.001_b0235","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2141.2009.07954.x","article-title":"Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma","volume":"148","author":"Bates","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0240","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-4614-0254-1_14","article-title":"Histone deacetylase inhibitor: antineoplastic agent and radiation modulator","volume":"720","author":"Konsoula","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0245","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.4161\/cc.10.18.17190","article-title":"Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer","volume":"10","author":"Luchenko","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ctrv.2014.08.001_b0250","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7164\/antibiotics.47.301","article-title":"FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity","volume":"47","author":"Ueda","year":"1994","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ctrv.2014.08.001_b0255","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/excr.1998.4027","article-title":"FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor","volume":"241","author":"Nakajima","year":"1998","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ctrv.2014.08.001_b0260","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","article-title":"Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors","volume":"409","author":"Khan","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.ctrv.2014.08.001_b0265","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ctrv.2014.08.001_b0270","first-page":"357","article-title":"Genetically engineered fusion proteins for treatment of cancer","volume":"9","author":"Weidle","year":"2012","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.ctrv.2014.08.001_b0275","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","article-title":"A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study","volume":"54","author":"Foss","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2014.08.001_b0280","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.2174\/092986706778742918","article-title":"Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity","volume":"13","author":"Robak","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ctrv.2014.08.001_b0285","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0290","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin\u2019s lymphomas. Version 3. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf; 2012."},{"key":"10.1016\/j.ctrv.2014.08.001_b0295","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0300","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2013an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2014.08.001_b0305","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/annonc\/mdg702","article-title":"Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"14","author":"Zelenetz","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0310","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3816\/CLM.2004.n.009","article-title":"Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma","volume":"5","author":"Emmanouilides","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.ctrv.2014.08.001_b0315","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2014.08.001_b0320","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1445-5994.2007.01397.x","article-title":"Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim","volume":"37","author":"Spencer","year":"2007","journal-title":"Intern Med J"},{"key":"10.1016\/j.ctrv.2014.08.001_b0325","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00277-008-0669-3","article-title":"l-Asparaginase in the treatment of refractory and relapsed extranodal NK\/T-cell lymphoma, nasal type","volume":"88","author":"Yong","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0330","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/annonc\/mdn542","article-title":"l-Asparaginase-based treatment of 15 western patients with extranodal NK\/T-cell lymphoma and leukemia and a review of the literature","volume":"20","author":"Jaccard","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0335","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of l-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.08.001_b0340","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0345","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.20009","article-title":"Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.08.001_b0350","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1349-7006.2006.00349.x","article-title":"Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma","volume":"98","author":"Niitsu","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2014.08.001_b0355","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/asheducation-2011.1.515","article-title":"Therapies for peripheral T-cell lymphomas","volume":"2011","author":"Savage","year":"2011","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1016\/j.ctrv.2014.08.001_b0360","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s10637-010-9523-2","article-title":"Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity","volume":"30","author":"Kim","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2014.08.001_b0365","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2011.08651.x","article-title":"Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)","volume":"153","author":"Dearden","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0370","doi-asserted-by":"crossref","first-page":"320624","DOI":"10.1155\/2010\/320624","article-title":"Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas","volume":"2010","author":"Reimer","year":"2010","journal-title":"Adv Hematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0375","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.beha.2012.01.007","article-title":"Autologous or allogeneic transplantation in B- and T-cell lymphomas","volume":"25","author":"Schmitz","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0380","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/annonc\/mdr140","article-title":"Stem-cell transplantation in T-cell non-Hodgkin\u2019s lymphomas","volume":"22","author":"Hosing","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0385","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0390","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0395","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2007.00815.x","article-title":"Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience","volume":"78","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0400","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","article-title":"Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey","volume":"33","author":"Jantunen","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2014.08.001_b0405","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bmt.1704392","article-title":"High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy sensitive ALK-negative anaplastic large-cell lymphoma","volume":"33","author":"Zamkoff","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2014.08.001_b0410","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodr\u00edguez","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0415","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2014.08.001_b0420","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0425","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0430","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0435","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0440","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2014.08.001_b0445","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2141.1999.01666.x","article-title":"Allogeneic bone marrow transplantation in aggressive non-Hodgkin\u2019s lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Soci\u00e9t Fran\u00e7aise de Greffe de Moelle","volume":"107","author":"Dhedin","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2014.08.001_b0450","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bmt.1705036","article-title":"Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin\u2019s lymphoma","volume":"36","author":"Wulf","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2014.08.001_b0455","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2141.2010.08210.x","article-title":"Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas","volume":"150","author":"Shustov","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T21:20:15Z","timestamp":1717276815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0305737214001455"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.08.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic options in relapsed or refractory peripheral T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}